Impact of tumour volume on outcomes in patients with locally advanced non-small cell lung cancer receiving chemoradiotherapy and consolidation durvalumab
British Journal of Radiology · 01.05.2026 · 99 (1181) · 999-1005
DOI: 10.1093/bjr/tqag048 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Radiology, online erschienen am 15.03.2026. Verfasst von Vincent Legendre und 7 weiteren Autor:innen. Beteiligte Einrichtung: Département d'Oncologie-Radiothérapie, Université Paris-Saclay, Gustave Roussy, Villejuif, 94805, France. Hauptthemen laut MEDLINE: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Antibodies, Monoclonal, Chemoradiotherapy. Die Arbeit nennt 34 Literaturangaben. Gefördert von: AstraZeneca.
Abstract (Originalsprache)
Objectives
The standard of care for unresectable locally advanced non-small-cell lung cancer (LA-NSCLC) is chemoradiotherapy (CRT) followed by consolidation immunotherapy. We analysed clinical, biological, and dosimetric data to identify survival predictors and inform personalized treatment strategies.
Methods
We retrospectively reviewed LA-NSCLC patients treated between December 2015 and January 2023. Data were extracted from electronic medical records. Progression-free survival (PFS) and overall survival (OS) were calculated from diagnosis. Kaplan-Meier estimates and Cox proportional hazards models were used for survival analysis.
Results
We included 92 patients (median follow-up: 28.9 months); 66% were male, 60% former smokers, and the median age was 64. Stage IIIB (50%) and adenocarcinoma (60%) were most common. PD-L1 positivity was observed in 75%, and 27% had oncogenic drivers (KRAS: 24%, EGFR: 3%). Most (86%) received concurrent CRT, typically cisplatin-based (60%). Median durvalumab duration was 9.5 months. Median PFS and OS were 31.9 and 51.2 months, respectively. Overall, 47% of patients experienced recurrence, including 15% locoregional recurrence and 85% metastatic recurrence (60% oligometastatic and 25% polymetastatic). PFS was longer in patients aged <66 years (45.4 vs 16.0 months; P = .01), with pre-RT lymphocyte counts >1.80 G/L (45.4 vs 27.7 months; P = .047), or PTV <450 cc (44.3 vs 16.1 months; P = .01). On multivariate analysis, only radiotherapy planning target volume (PTV) <450 cc remained significant (HR: 0.45; P = .04). No factor was associated with OS in multivariable analysis.
Conclusions
Smaller PTV was independently associated with longer PFS, supporting its value in personalized care for LA-NSCLC. Advances in knowledge PTV emerged as an independent prognostic factor for PFS, suggesting its utility in risk stratification and individualized treatment planning.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Département d'Oncologie-Radiothérapie, Université Paris-Saclay, Gustave Roussy, Villejuif, 94805, France.
- Faculty of Medicine, Paris Cité University, Paris, 75006, France.
- Département d'Oncologie Médicale, Université Paris-Saclay, Gustave Roussy, Villejuif, 94805, France.
- Université Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre, 94270, France.
- Electronics Architecture, Modeling and Data Analysis Laboratory, CEA, Gif-sur-Yvette, 91191, France.
- Université Paris-Saclay, Inserm U1355, Gustave Roussy, Villejuif, 94805, France.
ORCID-Profile: Vincent Legendre, Antonin Levy
Förderung
- AstraZeneca
Zitieren
APA
Legendre, V., Botticella, A., Beshiri, K., Lavaud, P., Aldea, M., Gambini, J., Le Péchoux, C., & Levy, A. (2026). Impact of tumour volume on outcomes in patients with locally advanced non-small cell lung cancer receiving chemoradiotherapy and consolidation durvalumab. British Journal of Radiology, 99(1181), 999-1005. https://doi.org/10.1093/bjr/tqag048
Vancouver
Legendre V, Botticella A, Beshiri K, Lavaud P, Aldea M, Gambini J, et al. Impact of tumour volume on outcomes in patients with locally advanced non-small cell lung cancer receiving chemoradiotherapy and consolidation durvalumab. British Journal of Radiology. 2026;99(1181):999-1005. doi:10.1093/bjr/tqag048
BibTeX
@article{Legendre2026,
author = {Legendre, Vincent and Botticella, Angela and Beshiri, Kristi and Lavaud, Pernelle and Aldea, Mihaela and Gambini, Jérôme and Le Péchoux, Cécile and Levy, Antonin},
title = {Impact of tumour volume on outcomes in patients with locally advanced non-small cell lung cancer receiving chemoradiotherapy and consolidation durvalumab},
journal = {British Journal of Radiology},
year = {2026},
volume = {99},
number = {1181},
pages = {999--1005},
doi = {10.1093/bjr/tqag048}
}
EUVIMED